Sciclone Pharmaceuticals Inc (SCLN) financial statements (2021 and earlier)

Company profile

Business Address 950 TOWER LANE
FOSTER CITY, CA 94404-2125
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments134101868684
Cash and cash equivalents134101868684
Short-term investments  0  
Restricted cash and investments   03
Receivables4239404038
Inventory, net of allowances, customer advances and progress billings1711111510
Inventory1711111510
Prepaid expense and other current assets22
Deferred tax assets 00  
Other undisclosed current assets3163  
Total current assets:196169140143137
Noncurrent Assets
Property, plant and equipment23211
Long-term investments and receivables  5  
Accounts and financing receivable, after allowance for credit loss  5  
Intangible assets, net (including goodwill)3133353534
Goodwill3133353534
Other noncurrent assets1312  
Other undisclosed noncurrent assets1 111
Total noncurrent assets:4648423737
TOTAL ASSETS:242217182180174
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2637353434
Accounts payable44578
Accrued liabilities2332212121
Employee-related liabilities  4  
Taxes payable  554
Debt   21
Deferred revenue and credits 013 
Deferred tax liabilities   00
Total current liabilities:2637363935
Noncurrent Liabilities
Liabilities, other than long-term debt00   
Other liabilities00   
Total noncurrent liabilities:00   
Total liabilities:2737363935
Stockholders' equity
Stockholders' equity attributable to parent215180155147143
Common stock00000
Additional paid in capital305296287278274
Accumulated other comprehensive income (loss)(2)2343
Accumulated deficit(88)(118)(135)(136)(134)
Total stockholders' equity:215180155147143
Other undisclosed liabilities and equity  (9)(5)(4)
TOTAL LIABILITIES AND EQUITY:242217182180174

Income statement (P&L) ($ in millions)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues160157135127156
Revenue, net15615413299123
Cost of revenue(37)(44)(2)  
Cost of goods and services sold(0) (2)  
Gross profit:123113133127156
Operating expenses(90)(83)(72)(93)(96)
Other undisclosed operating loss  (35)(24)(54)
Operating income:333026106
Nonoperating income (expense)1003(0)
Foreign currency transaction loss, before tax(2)(0)   
Other nonoperating income (expense)(0)(1)03(0)
Other undisclosed loss from continuing operations before equity method investments, income taxes    (0)
Income from continuing operations before income taxes:343026136
Income tax expense (benefit)(3)(1)(1)(2)3
Net income available to common stockholders, diluted:3129251110

Comprehensive Income ($ in millions)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net income:3129251110
Other comprehensive income (loss)  (1)11
Comprehensive income:3129241210
Other undisclosed comprehensive loss, net of tax, attributable to parent(4)(1)   
Comprehensive income, net of tax, attributable to parent:2728241210

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: